Investors — RadioLite Therapeutics

We are currently raising a $1.5M CAD pre-seed round

Funds will advance our lead candidate through GLP toxicology, GMP manufacturing, and IND-enabling studies. We welcome conversations with strategic investors, venture capital firms, and family offices with interest in oncology and nanomedicine.

Five million patients a year.

Radiotherapy is an indispensable treatment for 50% of all cancer patients in developed healthcare systems. However, radiotherapy's effectiveness is limited by the body's maximum safe radiation exposure. Higher doses could kill more cancer cells but would cause unacceptable damage to healthy tissue.

Current radiosensitizers have failed to provide clinically significant improvements due to highly toxic compounds, minimal additional benefit, and narrow biologic targets. Patients face permanent "late effects" and treatment limitations.

5 million patients are treated annually with radiotherapy in developed healthcare systems. Approximately 10% (500,000) can significantly benefit from higher efficacy and/or lower toxicity, at $50,000 per course of treatment. The total addressable market exceeds $25 billion.

Market opportunity by indication

$17.5B — Four most common cancers: Breast, colorectal, lung, and prostate (350,000 patients)
$1B — Glioblastoma brain tumours: Likely first indication — highest unmet need (20,000 patients)
$6.5B — All other radiotherapy indications: Deep-seated tumors where conventional PDT cannot reach (130,000 patients)

$25B+

Total Addressable Market

500,000 addressable patients across breast, colorectal, lung, prostate, and glioblastoma at $50,000 per course.

Intellectual property

A 2018 priority date, and a growing moat. A strong, defensible patent estate with early priority dates covering composition of matter, methods of use, and manufacturing.

Platform Patent

US application on platform technology with 2018 priority date, close to allowance. Covers the core nanoparticle architecture including the radiation-sensitive scintillator core (LaF3:Ce3+) and the photosensitizer coating (PPIX). Filed in US, EU, Canada, and China.

Continuation Patents

Built on the platform patent with additional claims for further niches as data develops. Accelerated at the patent office with 2026 completion target. Broad claims covering radiation-activated nanoparticles for treating solid tumors, with specific claims for glioblastoma, head and neck cancer, and pancreatic cancer.

Follow-On Patents

Filed in 2025, directed at technology developments (e.g., new selective release nanoparticles) and clinical applications. Proprietary synthesis and surface functionalization methods enable scalable, reproducible production with tight size distribution (~100 nm) and batch-to-batch consistency. >90% encapsulation efficiency demonstrated.

Strategic capital deployment

Raising $1.5M CAD to complete pre-phase 1 studies. Maximum impact for every dollar invested.

45%

Preclinical Data & Toxicology

40%

Staff & Production Facility

15%

Business Development & Overhead

Clear path to market

Near-term milestones with defined exit potential.

2024

Company Founded

Company incorporated, office space secured, research agreement with Sunnybrook established.

Q2 2025

Pre-Seed & Patents

4 patents submitted, strong pre-clinical evidence, hiring R&D team, closing pre-seed round.

Q3 2026

Scale & Regulatory

Standardise nanoparticle production, scaling laboratory, pre-CTA meeting with Health Canada.

Q2 2027

Toxicology & NDA

Preclinical toxicology studies to establish starting dosing for human trials. New Drug Application.

Q2 2028

Seed & Phase I

Seed funding round (est. $25M). Completing Phase 1 trials: efficacy and side effects.

Q3 2031

Phase II & Exit

Completing Phase 2 trials to establish superiority. Exit through M&A with larger pharmaceutical (est. $300M+).

Leadership & scientific team

Built by the people who invented it. Deep expertise in oncology, radiotherapy, and commercialization.

Dr. Deepak Dinakaran

Founder & CEO

MD PhD — Radiation oncologist at Sunnybrook, and inventor of the RadioPDT technology. PhD in Medical Biophysics from U of T. 4 patent families. Research published in ACS Nano, Frontiers in Bioengineering.

deepak@radioliteinc.com Lab Website ResearchGate

Julian Forman

Chief Operating Officer

JD — Intellectual property lawyer. Business development and operations. Drives strategic partnerships and IP portfolio management.

julian@radioliteinc.com

Dr. John Mackey

Chief Medical Officer

MD — Medical oncologist. Clinical development and regulatory experience. Leads clinical strategy and trial design.

johnrobertmackey@gmail.com

Investment Opportunity